Sponsor pipeline

Ambros Therapeutics, Inc. clinical trial pipeline

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

First posted	Trial	Phase	Status
2026-10-05	NCT07857733 Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain…	Phase 3	Not Yet Recruiting

Phase 3

Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT07210515	Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)	Complex Regional Pain Syndrome Type I	Recruiting	2026-09-10
NCT07857733	Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain…	Complex Regional Pain Syndrome Type I	Not Yet Recruiting	2026-10-14
Not specified
NCT07811362	CRPS-RISE Outcomes Registry	Complex Regional Pain Syndrome I (CRPS I)	Recruiting	2026-09-29

Get alerts when Ambros Therapeutics, Inc.'s trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.